Enlivex Therapeutics (NASDAQ:ENLV – Get Free Report)‘s stock had its “buy” rating reiterated by HC Wainwright in a note issued to investors on Tuesday, Benzinga reports. They presently have a $7.00 price target on the stock. HC Wainwright’s target price would indicate a potential upside of 366.67% from the stock’s previous close.
Enlivex Therapeutics Trading Up 13.6 %
NASDAQ:ENLV opened at $1.50 on Tuesday. The company has a market cap of $27.86 million, a PE ratio of -0.96 and a beta of 1.02. Enlivex Therapeutics has a twelve month low of $1.15 and a twelve month high of $4.59. The company’s 50 day moving average is $3.22 and its two-hundred day moving average is $2.53.
Enlivex Therapeutics (NASDAQ:ENLV – Get Free Report) last released its quarterly earnings data on Friday, March 29th. The company reported ($0.48) EPS for the quarter. As a group, analysts expect that Enlivex Therapeutics will post -0.86 EPS for the current fiscal year.
About Enlivex Therapeutics
Enlivex Therapeutics Ltd. operates as a clinical-stage macrophage reprogramming immunotherapy company. It is developing Allocetra, a cell-based therapy to treat organ dysfunction and failure associated with sepsis that is in phase II clinical trial, as well as in preclinical trial to treat solid tumors.
See Also
- Five stocks we like better than Enlivex Therapeutics
- High Dividend REITs: Are They an Ideal Way to Diversify?
- High-Yield Texas Instruments Could Hit New Highs Soon
- How the NYSE and NASDAQ are Different, Why That Matters to Investors
- Pagaya Technologies: An AI Fintech That Insiders Are Buying
- The How And Why of Investing in Oil Stocks
- Higher Oil Prices Could Give NextEra’s Stock Earnings a Boost
Receive News & Ratings for Enlivex Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enlivex Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
